RAPACT 10MG TABLETS | EVEROLIMUS | MHP
                     RAPACT 10MG TABLETS | 
EVEROLIMUS | MHP
Million Health Pharmaceuticals
DESCRIPTION:
• Rapact 10mg is a derivative of Rapamycin 
(sirolimus) and works similarly to Rapamycin 
as an mTOR (mammalian target of rapamycin) 
inhibitor. It is normally used as an 
immunosuppressant to prevent rejection of 
organ transplants. 
In a similar fashion to other mTOR inhibitors 
Everolimus' effect is solely on the mTORC1 
protein and not on the mTORC2 protein.
Breast carcinoma
PRESCRIBING INFORMATION:
• Rapact 10mg tablet are mainly indicated for 
the treatment of Renal carcinoma.
Rapact 10mg tablet are mainly indicated for 
the treatment of Breast carcinoma.
Rapact 10mg tablet are mainly indicated for 
the treatment of Brain carcinoma.
Rapact 10mg is also used in various advanced 
stage cancer in stomach, intestines or 
pancreas.
MECHANISM OF ACTION:
• Everolimus is an mTOR prohibitor, joints at high 
compatibility to FK506 binding protein 12, via 
producing drug complex which inhibits the 
specific of mTOR.
This inhibition decreases the activity of effectors 
downstream, that may cause blockage of cell 
progression from G1 into S phase, subsequently 
causes cell growth arrest and apoptosis
RAPACT 10MG
PRODUCT DETAILS:
• Brand : Rapact 
Ingredients : Everolimus 
Strength : 10mg
Manufactured : Natco Pharma Ltd 
Package : 10 tablets 
PHARMACOKINETICS
• ABSORPTION:
• The high plasma concentration time of Everolimus is 1 
to 2 hours.
DISTRIBUTION:
• Rapact 10mg human plasma protein bound with the 
range of 74%.
METABOLISM:
• The metabolism of Everolimus is occurred in liver, 
which is a substrate of CYP3A4.
The metabolites of Everolimus;
EXCRETION:
• The major route of elimination; 
5% in urine; the parent compound has been 
detected in urine or feces. 
The half-life period of Everolimus is relatively 
30 hours
DOSAGE MANAGEMENT:
• In breast cancer, renal cell cancer, pancreatic cancer, Neuro 
endocrine cancer:
The prescribed dosage is rapact 10mg should be taken as a single 
dose.
In Brain or intracranial cancer:
The prescribed dosage of Rapact 10mg is 4.5mg/m2 orally as a 
single dose.
In pediatric:
The usual pediatric dosage of Rapact 10mg tablet in brain or 
intracranial tumor is 4.5mg/m2 should be taken orally as a single 
dose. 
Rapact 10mg tablet should be administered with or without food.
PRECAUTIONS:
• Lymphomas:
• Increased exposure of skin cancers, patient may protect 
from UV light
Serious infections:
• Patients receiving Rapact 10mg have high risk of acquiring 
various infections related to bacteria, virus, and fungi. Anti-
microbial agents are preferred for the suspected patients.
Hepatic artery thrombosis:
• In liver transplant patients, Rapact 10mg therapy should 
not be recommended.
SIDE EFFECTS:
• Hypersensitivity reactions
• Lymphomas & other malignancy
• Serious infections
• Kidney graft thrombosis
• Hepatic artery thrombosis
• Nephrotoxicity
• Hyperlipemia
• Angioedema
• Interstitial lung disease
• Thrombocytopenia
• Male infertility
• Proteinuria
• New commencement of diabetes .
DRUG INTERACTION:
• Rapact 10mg interaction with strong inhibitor of CYP3A4, or P-
gp, leads to cause decreasing the efflux of Everolimus and 
increase the plasma concentration of Everolimus.
• Combination of Rapact 10mg with verapamil leads to increasing 
the plasma concentration of Everolimus.
• Combination of Rapact 10mg with Atorvastatin or pravastatin 
causes rhabdomyolysis, due to increasing concentration of lipid 
lowering agents.
• Rapact 10mg combination with strong CYP3A4 inducers, causes 
increasing the exposure of Everolimus.
• Concomitant use of Rapact 10mg with cyclosporine causes 
increasing the AUC level of Everolimus frequently.
CONTRAINDICATIONS:
• Some anaphylactic reaction occurs, if patients 
are contraindicated to the components 
present in the Rapact 10mg tablet.
PREGNANCY:
• Pregnancy category C Rapact 10mg is needed 
only by the patients after knowing the 
benefits to the mother outweighs the risk to 
fetus.
LACTATION:
• Breast feeding should not be suggested
STORAGE :
• Rapact 10mg tablet should be kept at 25°C
Keep the tablet away from moisture, heat and 
light
Dispense only in original container.
MISSED DOSE:
• If patient failed to take a single dose, patients 
must consult with medical practitioner and 
follow the instructions given by them. Or the 
missed dose should be avoiding and follow the 
regular dosing schedule.
OVERDOSAGE:
• The over dosage of Everolimus is rarely occur, 
in case of over dosage patient must be provide 
with supportive measures. The acute toxicity 
of Everolimus over dosage should be 
monitored.
CONTACT DETAIL:
• PHONENO:+91-9940472902
• EMAIL:[email protected]
• WEBSITE URL:
https://millionpharma.com/rapact-10-mg.php